赛生药业(06600.HK):药监局受理抗菌药物临床试验申请

阿斯达克财经
Dec 28, 2022

赛生药业(06600.HK) 公布,国家药监局药品审评中心(CDE)正式受理公司新型抗菌药物Vaborem(注射用美罗培南韦博巴坦)的临床试验申请。此临床试验申请包括一项III期临床研究,其目的是评估药物在中国复杂尿路感染(cUTI),包括肾盂肾炎患者中的疗效和安全性;以及一项针对中国健康志愿者的药代动力学研究,以评估其药代动力学特征。这两项在中国开展的临床研究用于桥接国外临床试验数据,并支持药物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10